TY - JOUR
T1 - Impact of intensified prevention measures on rates of hospital-acquired bloodstream infection in medicalsurgical intensive care units, Israel, 2011 to 2019
AU - Ben-David, Debby
AU - Vaturi, Azza
AU - Wulffhart, Liat
AU - Temkin, Elizabeth
AU - Solter, Ester
AU - Carmeli, Yehuda
AU - Schwaber, Mitchell J.
N1 - Publisher Copyright:
© 2023 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2023/6/22
Y1 - 2023/6/22
N2 - Background: Central line-associated bloodstream infection (CLABSI) is among the most common preventable infectious complications in patients in intensive care units (ICU). In 2011, the Israel National Center for Infection Control initiated a nationwide CLABSI prevention programme. Aim: To evaluate the impact of different components of the programme on CLABSI and non-CLABSI rates in medical-surgical ICUs. Methods: We included data collected from all 29 medical-surgical ICUs in Israel from November 2011 to December 2019. The study period was divided into three phases: I (baseline, initial CLABSI prevention guidelines introduced, initial feedback on rates provided), II (initial guidelines widely implemented, surveillance undertaken, feedback continued) and III (after implementation of additional prevention measures). Interrupted time series analysis was used to compare CLABSI and non-CLABSI rates during the three phases. Results: The pooled mean (SD) incidence of CLABSI per 1,000 central line-days dropped from 7.4 (0.38) in phase I to 2.1 (0.13) in phase III (p < 0.001). The incidence rate ratio (IRR) was 0.63 (95% CI: 0.51-0.79) between phases I and II, and 0.78 (95% CI: 0.59-1.02) between phases II and III. The pooled mean (SD) incidence of non-CLABSI per 1,000 patient-days declined from 5.3 (0.24) in phase I to 3.4 (0.13) in phase III (p < 0.001). Conclusion: National CLABSI prevention guidelines, surveillance and feedback resulted in significant reductions in CLABSI and non-CLABSI rates. In the wake of further interventions, significant reduction was achieved in ICUs reporting improvement in the uptake of additional prevention measures.
AB - Background: Central line-associated bloodstream infection (CLABSI) is among the most common preventable infectious complications in patients in intensive care units (ICU). In 2011, the Israel National Center for Infection Control initiated a nationwide CLABSI prevention programme. Aim: To evaluate the impact of different components of the programme on CLABSI and non-CLABSI rates in medical-surgical ICUs. Methods: We included data collected from all 29 medical-surgical ICUs in Israel from November 2011 to December 2019. The study period was divided into three phases: I (baseline, initial CLABSI prevention guidelines introduced, initial feedback on rates provided), II (initial guidelines widely implemented, surveillance undertaken, feedback continued) and III (after implementation of additional prevention measures). Interrupted time series analysis was used to compare CLABSI and non-CLABSI rates during the three phases. Results: The pooled mean (SD) incidence of CLABSI per 1,000 central line-days dropped from 7.4 (0.38) in phase I to 2.1 (0.13) in phase III (p < 0.001). The incidence rate ratio (IRR) was 0.63 (95% CI: 0.51-0.79) between phases I and II, and 0.78 (95% CI: 0.59-1.02) between phases II and III. The pooled mean (SD) incidence of non-CLABSI per 1,000 patient-days declined from 5.3 (0.24) in phase I to 3.4 (0.13) in phase III (p < 0.001). Conclusion: National CLABSI prevention guidelines, surveillance and feedback resulted in significant reductions in CLABSI and non-CLABSI rates. In the wake of further interventions, significant reduction was achieved in ICUs reporting improvement in the uptake of additional prevention measures.
UR - http://www.scopus.com/inward/record.url?scp=85164040799&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2023.28.25.2200688
DO - 10.2807/1560-7917.ES.2023.28.25.2200688
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37347415
AN - SCOPUS:85164040799
SN - 1025-496X
VL - 28
JO - Eurosurveillance
JF - Eurosurveillance
IS - 25
M1 - A1
ER -